• 3 dirt cheap ASX shares to buy before it is too late

    Man in white business shirt touches screen with happy smile symbol

    Although a number of shares have been hitting 52-week or record highs this week like Afterpay Ltd (ASX: APT), not all shares are trading close to these levels.

    A few top ASX shares are still trading at levels which I think make them cheap. Here’s why I would buy them:

    Aristocrat Leisure Limited (ASX: ALL)

    The Aristocrat Leisure share price is down 30% from its 52-week high. The catalyst for this decline has been the closure of casinos during the pandemic. As well as losing out on potential sales, the company was missing out on daily fees for its poker machines. The good news is that casinos are reopening and demand should soon pick up for its industry-leading machines. Another positive is that during the pandemic the company’s digital business has been booming. It now has 7.3 million daily active users playing its games which are generating significant recurring revenues.

    Sydney Airport Holdings Pty Ltd (ASX: SYD)

    The Sydney Airport share price has fallen 35% from its 52-week high. This has of course been driven by the collapse in tourism because of the pandemic. However, I feel this decline has been excessive and created a buying opportunity for patient investors. Especially with tourism markets likely to start recovering in the coming months. I expect domestic tourism to begin its recovery in the near future, with international tourism to follow in 2021. Based on this, I believe the company’s dividend could return to previous levels in 2022.

    Telstra Corporation Ltd (ASX: TLS)

    The Telstra share price is down 20% from its 52-week high, which I think is a buying opportunity for investors. This is because after years of struggles, the telco giant appears to be close to returning to growth. Especially given the early success of its T22 strategy, which is creating a much leaner operation. Combined with easing NBN headwinds and the arrival of 5G internet, I think Telstra could prove to be a great long term investment.

    And here are five dirt cheap ASX shares which analysts expect to rebound very strongly when the crisis passes…

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off it’s high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Telstra Limited. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 dirt cheap ASX shares to buy before it is too late appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2M8Pt46

  • 2 ASX 200 tech shares I’d like to buy today

    Circuit board, Altium shares

    S&P/ASX 200 Index (ASX: XJO) tech stocks have been volatile in 2020, but it has been a mixed bag of performances. Not every ASX 200 tech share has performed as well as Afterpay Ltd (ASX: APT) this year, which means there are many still in the buy zone.

    Here are a couple of my top picks that are trading at a good price today.

    2 ASX 200 tech shares I’d like to buy today

    I think Xero Limited (ASX: XRO) shares are worth a look right now. The Xero share price has rocketed 343.86% higher in the last 5 years but has edged just 6.25% higher in 2020.

    Xero provides accounting software platform to small and medium-sized businesses and could see steady earnings despite the coronavirus pandemic.

    While some customers may not renew their subscriptions, I think the complexity arising from the JobKeeper stimulus package could be where Xero comes into its own. That’s good for earnings and the Xero share price.

    I also like the look of Altium Limited (ASX: ALU) shares right now.

    Altium provides electronics design software for engineers who design printed circuit boards. As the global economy emerges from hibernation, I think business could pick up again for this Aussie tech group.

    Altium shares are up 19.77% this year, which means its already a strong performer. However, it is currently trading at $37.02 per share (at the time of writing), compared to an all-time high of $42.76.

    I think Altium could be an ASX top 50 or even top 20 share within the next decade. With a $4.85 billion market capitalisation right now, Altium is well-placed to capitalise on the changing tech scene here in Australia.

    Foolish takeaway

    Both Altium and Xero are successful ASX 200 tech shares that have rocketed higher in recent years.

    However, I think a recovering economy and strong client base could be the key to boost both share prices even higher in 2020.

    For more companies to add to your watchlist, check out these 5 cheap ASX shares today!

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off it’s high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Xero. The Motley Fool Australia owns shares of Altium. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 2 ASX 200 tech shares I’d like to buy today appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2AgrLQH

  • Novavax (NVAX) Stock Is a Winner, but How Much Higher Can It Go?

    Novavax (NVAX) Stock Is a Winner, but How Much Higher Can It Go?Volatility is nothing new in the healthcare sector. Nonetheless, vaccine player Novavax’s (NVAX) recent spectacular moon bound rally is on another level.The stock surged by another 147% this month, cumulatively accruing 1025% of gains in 2020. Which begs the far-fetched question: Has Novavax provided the coveted vaccine? Not yet, but it is taking some big strides towards addressing the issue.The latest share appreciation came following news that the coalition for Epidemic Preparedness Innovations (CEPI) will commit up to $388 million to further the development of Novavax’ vaccine candidate against COVID-19 (SARS-CoV-2), NVX-CoV2373. The investment is CEPI’s biggest to date and follows on from what now feels like a miniscule initial $4 million grant to Novavax.In tandem with setting the process of clinical trials in motion (with Phase 1/2 trial data expected by July), part of the funding will go towards ramping up production at various locations around the globe, with a target of matching the largest pharma vaccine developers’ production capacity.Based on Novavax’ vaccine track record, Ladenburg Thalmann analyst Michael Higgins is confident in the outcome, and predicts the Phase 1/2 results “will prove to be safe.” The results are key to his thesis of Novavax’ rNPV (risk-adjusted net present value) as the data will have an impact on the “scale up activities.”Higgins expounded, “While CEPI and Novavax are working collectively to generate the manufacturing capabilities to reach one billion doses in 2021, we are modeling the 100M doses are sold in 2021 at $10/dose, with 50% net margins. Mgt has not provided guidance on our assumptions; but given the low net manufacturing costs (especially on a large scale) we believe our assumptions are within reasonable expectations. We believe the low manufacturing margins contributed to CEPI’s decision, as it seeks to partner with innovators to treat as many global citizens as possible.”Overall, Novavax gets 100% support from the Street, as all 5 analysts tracked over the last 3 months rate the vaccine player a Buy. With an average price target of $49.20, the analyst fraternity projects upside of nearly 10%. (See Novavax stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/36DWtPS

Sorry, but nothing was found. Please try a search with different keywords.